Video
Dr. Udit Verma on Regorafenib in Patients With mCRC
Author(s):
Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer.
Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).
In the phase IIIB CONSIGN study, 2872 patients with mCRC who failed standard therapy were treated with regorafenib, which demonstrated a median progression-free survival of 2.7 months. This retrospective subgroup analysis sought to confirm previous findings as well as the safety profile of regorafenib. This study’s primary endpoint was safety, Verma adds.
The most common grade 3 adverse events were hand-foot skin reaction (16%), hypertension (15%), fatigue, and diarrhea. These findings were similar as to what was reported in the phase III CORRECT trial, Verma explains.
